This study is looking into the safety of a drug called AZD6750, which is an immunotherapy. It's for adults with certain advanced or metastatic (spread to other parts of the body) solid tumors, including melanoma, non-small cell lung cancer, skin squamous cell carcinoma, renal cell carcinoma (kidney cancer), and Merkel cell carcinoma. Some participants will receive AZD6750 alone, while others may receive it in combination with rilvegostomig, another immunotherapy drug. Researchers will also look at how well these treatments work. To join, you need to be at least 18 years old, have a good general health status (ECOG PS of 0 to 1), and have a tumor sample available for testing. Your body weight must be at least 35 kg, and you need to have adequate organ function. The study plans to enroll about 60 participants.

Study design

This is an open-label study, meaning both you and your doctors will know which treatment you are receiving. It is a Phase I/II study, which means it will first look at safety and then at how well the treatment works, and plans to enroll about 60 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Your safety will be monitored from the start of the study until 90 days after your last dose. If you are in the part of the study looking at how well the treatment works, your progress will be measured every 6 weeks for 48 weeks, and then every 12 weeks until your disease progresses or you pass away, which is expected to be about 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.